Table 3.
Univariate analysis of relapse free survival (RFS) according to pharmacogenotypes
| Polymorphisms | Caucasian series (n = 17/94)* | Vietnamese series (n = 33/141)* | Pooled series (n = 50/235)* | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Hazard ratios (95% CI) | Raw P value | Adjusted P value¥ | Hazard ratios (95% CI) | Raw P value | Adjusted P-value¥ | Hazard ratios (95% CI) | Raw P value | Adjusted P value¥ | |
| CCND1 G870A | |||||||||
| G/G – G/A | 1 | 1 | 1 | ||||||
| A/A | 0.70 (0.20, 2.42) | 0.57 | 1.00 | 2.05 (0.77, 5.45) | 0.15 | 1.00 | 1.20 (0.57, 2.53) | 0.63 | 1.00 |
| GGH C452T | |||||||||
| C/C | 1 | 1 | 1 | ||||||
| C/T | 1.79 (0.63, 5.09) | 0.28 | 1.00 | 0.73 (0.17, 3.19) | 0.67 | 1.00 | 1.32 (0.57, 3.06) | 0.51 | 1.00 |
| MTHFR C677T | |||||||||
| C/C | 1 | 1 | 1 | ||||||
| C/T – T/T | 1.09 (0.41, 2.84) | 0.87 | 1.00 | 1.05 (0.39, 2.8) | 0.93 | 1.00 | 1.08 (0.54, 2.15) | 0.83 | 1.00 |
| MTHFR A1298C | |||||||||
| A/A | 1 | 1 | 1 | ||||||
| A/C – C/C | 1.18 (0.45, 3.06) | 0.73 | 1.00 | 1.14 (0.45–2.91) | 0.78 | 1.00 | 1.14 (0.59, 2.23) | 0.69 | 1.00 |
| TSER | |||||||||
| 2R/2R – 2R/3R | 1 | 1 | 1 | ||||||
| 3R/3R – 3R/4R | 1.08 (0.40, 2.91) | 0.89 | 1.00 | 2.37 (0.68–8.27) | 0.18 | 1.00 | 1.48 (0.72, 3.05) | 0.28 | 1.00 |
| TPMT (*3A and *3C) | |||||||||
| No mutation | 1 | 1 | 1 | ||||||
| Mutation | 6.07 (1.36, 27.0) | 0.02 | 0.37 | 0.66 (0.09–5.04) | 0.69 | 1.00 | 1.51 (0.45, 5.05) | 0.50 | 1.00 |
| ITPA | |||||||||
| A/A A/C | 1 | 1 | 1 | ||||||
| CC | 2.91 (0.40, 22.0) | 0.30 | 1.00 | 1.39 (0.5–3.91) | 0.53 | 1.00 | 1.69 (0.69, 4.14) | 0.25 | 1.00 |
*
Number of relapse/number of children. ¥Bonferroni adjusted P values for multiple (n = 21) testing.